Investment
Features
FeesSafety
Academy
More
Pluang+

Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Shiba Inu euro trading shows wide spread gaps, impacting trader costs across exchanges.

On October 19, Shiba Inu (SHIB) trading against the euro revealed significant differences in bid-ask spreads across exchanges, with Kraken and Bit2Me showing tight spreads around 0.022%, while WhiteBIT had a much wider spread of 0.670%. This large variation means traders using the same currency pair could face very different costs depending on the exchange. SHIB euro pairs accounted for a small portion of total SHIB trading volume, with Tether pairs dominating. The data highlights the importance of exchange choice for traders due to liquidity and pricing differences, though spreads and turnover reflect different aspects of market activity.

Shiba Inu (SHIB) euro pairs show a wide spread gap across venues, contrasting Kraken and Bit2Me's tight spreads near 0.022% with WhiteBIT's much wider 0.670%. For readers following the broader cryptocurrency market, here is Pluang's snapshot as of Oct 20, 2026 08:21 WIB: among 50 major cryptocurrencies, 16 rose and 33 fell. Notable movers include CRV at Rp6.589 (+2.38%) with 99% sell orders, XNO at Rp6.016 (-2.24%) with balanced buy-sell activity, and ALGO at Rp1.970 (-2.18%) with predominantly sell orders and the longest typical hold time of 130 days on Pluang.

More News

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Socialism gains political ground in US, prompting free market advocates to strengthen their case for capitalism.

Socialism is rising in popularity within U.S. politics, particularly among those identifying as democratic socialists who seek a system more like European social democracy. Sam Gregg of the American Institute for Economic Research highlights the need...

Market News
Neutral
4 hours ago
Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

Researchers simulate a 50-qubit quantum computer using NVIDIA's JUPITER, setting a new benchmark in quantum computing.

The Jülich Supercomputing Centre and NVIDIA used the JUPITER supercomputer to simulate a universal 50-qubit quantum computer, surpassing their previous 48-qubit record from 2019. This full-state simulation required 2,048 TiB of memory, achieved throu...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App